NIDO (Boston, MA) is a medical device company developing SEPIA, an innovative solution for epicardial ablation of ventricular tachycardia (VT) based on technology developed at Boston Children’s Hospital. SEPIA will allow real-time visualization of the epicardial surface and provide angle and force control to an ablation catheter. Ultimately, it will reduce complications and improve ablation efficiency, leading to decrease recurrence of VT.

The company was co-founded by Dr. Pedro del Nido, Chairman of Cardiovascular Surgery and Professor at Harvard Medical School, and Dr. Nikolay Vasilyev, former Assistant Professor of Surgery at Harvard Medical School, currently Medical Director for the Surgicals Portfolio at Pfizer.